Aerosolized formulation

Abstract

An aerosolized formulation is provided, comprising: (i) water in an amount of at least 50 wt.% based on the aerosolized formulation; and (ii) at least one fragrance, wherein the at least one fragrance is in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation is generated.

Description

Field of the Invention

[0001] The present disclosure relates to aerosolized formulations, methods for generating aerosolized formulations, devices for generating aerosolized formulations, and methods and uses of aerosolized formulations. Background of the Invention

[0002] Electronic aerosol delivery systems, such as e-cigarettes, generally include a reservoir of a liquid to be vaporized that typically contains flavorants or active agents such as nicotine. When a user inhales on the device, a heater is activated to vaporize a small amount of the liquid, and thus the vaporized liquid is inhaled by the user.

[0003] The use of e-cigarettes in the UK has increased rapidly and it is now estimated that over one million people in the UK use e-cigarettes.

[0004] One challenge in providing such a system is to supply an inhaled aerosol from an aerosol supply device that provides an acceptable experience to the consumer. Some consumers may prefer e-cigarettes that generate an aerosol that closely "resembles" the smoke inhaled from tobacco products such as cigarettes. The aerosol from e-cigarettes and the smoke from tobacco products such as cigarettes result in a complex chain of flavors in the user's mouth and, when nicotine is present, nicotine absorption in the mouth and throat, followed by nicotine absorption in the lungs. These various aspects have been described by users in terms of flavor, strength / quality, impact, harshness / smoothness, and reward. Flavors contribute to some of these factors and are strongly related to the flavor in the mouth and the achievement of desirable tastes and scents, whether mimicking the taste and smell of tobacco products or achieving alternative flavors. Ensuring the realization of specific tastes and scents is made more difficult by the volatile and thermally sensitive nature of some flavors. Heating of flavor components in e-cigarettes can lead to the decomposition of some flavors. This has several disadvantages. There is a risk that the flavors present in the liquid are lost, reducing the user's flavor experience, or that it becomes necessary to include excessive flavors in the liquid at additional cost. Furthermore, if the e-liquid contains multiple flavors and only some of these multiple flavors are decomposed, this can negatively affect the balance of taste and smell. Additionally, the decomposed flavors may be undesirable or have an "off taste". Each of these factors, and the balance of the factors, can strongly contribute to the consumer acceptance of e-cigarettes. Therefore, means for optimizing the overall vaping experience are desirable for e-cigarette manufacturers.

[0005] A further challenge faced by such a system is the ongoing demand for harm reduction. The harm caused by cigarettes and e-cigarette devices mainly stems from poisons. Therefore, it is desirable to reduce the potential for the generation of poisons. SUMMARY OF THE INVENTION

[0006] In one aspect, there is provided an aerosolized formulation comprising (i) water in an amount of at least 50 wt.% based on the aerosolized formulation, and (ii) at least one fragrance wherein the aerosolized formulation contains at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced.

[0007] In one aspect, there is provided a method for producing an aerosol, comprising (i) aerosolizing an aerosolizable formulation comprising water in an amount of at least 50 wt.% based on the aerosolized formulation, and (ii) at least one fragrance to produce an aerosol containing at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation.

[0008] In one aspect, there is provided an electronic aerosol supply system comprising (a) an aerosolizing device for aerosolizing a formulation for inhalation by a user of the electronic aerosol supply system; (b) a power source comprising a battery or battery pack for supplying power to the aerosolizing device; (c) (i) water in an amount of at least 50 wt.% based on the aerosolized formulation, and (ii) at least one fragrance wherein the aerosolizing device produces an aerosol containing at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation.

[0009] In one aspect, there is provided a method for improving the delivery of a fragrance to an aerosolized formulation, comprising ​(a) Preparing an aerosolizable material comprising (i) water in an amount of at least 50 wt.% based on the aerosolizable material, and (ii) at least one fragrance; (b) Aerosolizing the aerosolizable material to produce an aerosol comprising at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation from which the aerosolizable formulation is produced A method is provided that includes. Detailed description

[0010] As discussed herein, in one aspect, an aerosolized formulation comprising (i) water in an amount of at least 50 wt.% based on the aerosolized formulation, and (ii) at least one fragrance is provided, wherein the aerosolized formulation contains at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced.

[0011] The inventors have found that aerosolized formulations containing high levels of water and fragrance can provide an advantageous system produced from an aerosolizable formulation. The use of systems containing at least 50 wt% water "protects" the fragrance from thermal degradation and, in particular, enables the production of aerosolized formulations at low temperatures. This is in contrast to "conventional" e-cigarettes that typically use liquids based on glycerol and propylene glycol and a heater to produce an aerosolized formulation.

[0012] For ease of reference, these and further aspects of the invention are discussed below under appropriate section headings. However, the teachings of each section are not necessarily limited to each particular section.

[0013] Water As discussed herein, the aerosolized formulation comprises water in an amount of at least 50 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 55 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 60 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 65 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 70 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 75 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 80 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 85 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 90 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 95 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of at least 99 wt.% based on the aerosolized formulation.

[0014] In one embodiment, water is present in an amount of 50 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 55 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 60 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 65 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 70 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 75 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 80 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 85 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 90 to 99 wt.% based on the aerosolized formulation. In one embodiment, water is present in an amount of 95 to 99 wt.% based on the aerosolized formulation.

[0015] As discussed herein, the aerosolizable formulation contains water in an amount of at least 50 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 55 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 60 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 65 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 70 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 75 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 80 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 85 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 90 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 95 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of at least 99 wt.% based on the aerosolizable formulation.

[0016] In one embodiment, water is present in an amount of 50 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 55 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 60 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 65 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 70 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 75 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 80 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 85 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 90 to 99 wt.% based on the aerosolizable formulation. In one embodiment, water is present in an amount of 95 to 99 wt.% based on the aerosolizable formulation.

[0017] As discussed herein, the use of water enables substitution of some or all of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof typically used in e-cigarettes. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 10 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 8 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 5 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 2 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 1 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 0.5 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof of 0.2 wt.% or less based on the aerosolizable formulation or the aerosolized formulation.In one aspect, the aerosolizable formulation contains glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof in a combined amount of 0.1 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof in a combined amount of 0.01 wt.% or less based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation does not contain glycerol, propylene glycol, 1,3-propanediol, and mixtures thereof.

[0018] In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 10 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 8 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 0.5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 0.2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 0.1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises a combined amount of glycerol, propylene glycol, and mixtures thereof that is 0.01 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation.In one aspect, the aerosolizable formulation does not contain glycerol, propylene glycol, and mixtures thereof.

[0019] In one aspect, the aerosolizable formulation contains glycerol in an amount of 10 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 8 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 0.5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 0.2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 0.1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation contains glycerol in an amount of 0.01 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one aspect, the aerosolizable formulation does not contain glycerol.

[0020] In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 10 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 8 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 0.5 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 0.2 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation comprises propylene glycol in an amount of 0.1 wt.% or less, based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the aerosolizable formulation does not contain propylene glycol.

[0021] Spice As discussed herein, the aerosolized formulation contains at least one fragrance in an amount of at least 70 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 75 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 80 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 85 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 90 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 95 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 98 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced. In one embodiment, the aerosolized formulation contains at least one fragrance in an amount of at least 99 wt% of said fragrance present in the aerosolizable formulation from which the aerosolized formulation is produced.

[0022] In one aspect, the aerosolized formulation contains more than one fragrance. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 70 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 75 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 80 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 85 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 90 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 95 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 98 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced. In one aspect, when the aerosolized formulation contains a plurality of fragrances, the aerosolized formulation contains each of the plurality of fragrances in an amount of at least 99 wt% of the fragrance present in the aerosolizable formulation from which the aerosolized formulation was produced.

[0023] The aerosolizable formulation contains one or more fragrances or flavoring ingredients. As used herein, the terms "fragrance" and "flavor" refer to materials that can be used, where local control permits, to create a desired taste or scent in products for adult consumers. Fragrances and flavorings include extracts (such as licorice, hydrangea, phoebe leaf, chamomile, fenugreek, clove, menthol, Japanese mint, aniseed, cinnamon, herbs, wintergreen, strawberry, berry, peach, apple, drambuie, bourbon, scotch, whiskey, spearmint, peppermint, lavender, cardamom, celery, cascarilla, nutmeg, frankincense, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, cassia, caraway, cognac, jasmine, ylang-ylang, sage, perilla, pepper, ginger, anise, coriander, coffee, or peppermint oil from any species of the genus Mentha), flavor enhancers, bitter receptor site blockers, sensory receptor site activators or sensory receptor site stimulants, sugars and / or alternative sugars (such as sucralose, acesulfame potassium, aspartame, saccharin, thaumatin, lactose, sucrose, glucose, fructose, sorbitol or mannitol), and other additives such as charcoal, chlorophyll, minerals, vegetable substances or breath fresheners. These may be imitation, synthetic or natural raw materials or blends thereof. These may be in any suitable form, such as an oil, liquid or powder. One or more fragrances may be selected from the group consisting of (4-(para-)methoxyphenyl)-2-butanone, vanillin, γ-undecalactone, menthone, 5-propenylguaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof. In one embodiment, the fragrance is at least menthol.

[0024] When present, the one or more fragrances may be present in any suitable amount. In one embodiment, the one or more fragrances are present in a total amount of 10 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 7 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 5 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 4 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 3 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 2 wt.% or less based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 1 wt.% or less based on the aerosolizable formulation.

[0025] In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 5 wt.% based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 4 wt.% based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 3 wt.% based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 2 wt.% based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 1 wt.% based on the aerosolizable formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 0.5 wt.% based on the aerosolizable formulation.

[0026] In one embodiment, the one or more fragrances are present in a total amount of 10 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 7 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 5 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 4 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 3 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 2 wt.% or less based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 1 wt.% or less based on the aerosolized formulation.

[0027] In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 5 wt.% based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 4 wt.% based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 3 wt.% based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 2 wt.% based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 1 wt.% based on the aerosolized formulation. In one embodiment, the one or more fragrances are present in a total amount of 0.01 - 0.5 wt.% based on the aerosolized formulation.

[0028] Activator The aerosolizable formulation and the aerosolized formulation of the present invention may contain one or more additional components. These components may be selected according to the nature of the formulation. In one aspect, the aerosolizable formulation and the aerosolized formulation further contain an active agent. By "active agent" is meant a drug that has a biological effect on a subject when the aerosol is inhaled. The active agent may be selected, for example, from nutraceuticals, nootropics, and psychotropic drugs. The active substance may be naturally occurring or synthetically obtained. The active agent may include, for example, nicotine, caffeine, taurine, theine, vitamins such as B6 or B12 or C, melatonin, cannabinoids or their constituents, derivatives or combinations. The active agent may include one or more constituents, derivatives or extracts of tobacco, cannabis or other plant substances. In some embodiments, the active agent includes caffeine, melatonin or vitamin B12. One or more active agents may be selected from nicotine, plant substances and mixtures thereof. One or more active agents may be of synthetic or natural origin. The active agent may be an extract from a plant substance such as from a plant of the Solanaceae family. An example of an active agent is nicotine.

[0029] As described herein, the active agent may include one or more components, derivatives or extracts of cannabis, such as one or more cannabinoids or terpenes. Cannabinoids are a class of natural or synthetic compounds that act on cannabinoid receptors (i.e., CB1 and CB2) within cells and suppress neurotransmitter release in the brain. Cannabinoids may be naturally occurring, derived from plants such as cannabis (phytocannabinoids), from animals (endocannabinoids), or may be artificially manufactured (synthetic cannabinoids). Cannabis seeds express at least 85 different phytocannabinoids, which are divided into subclasses including cannaguerols, cannabinochromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, as well as other cannabinoids. Cannabinoids found in cannabis include, without limitation: cannabigerol (CBG), cannabinochromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabinochromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinolic acid, cannabidiolic acid (CBDA), cannabinol propyl variant (CBNV), cannabinotriol (CBO), tetrahydrocannabinolic acid (THCA) and tetrahydrocannabivarinic acid (THCV A).

[0030] In some embodiments, the active agent includes one or more components, derivatives or extracts of cannabis.

[0031] As described herein, the active agent may include one or more plant substances or their components, derivatives or extracts, or may be derived therefrom. As used herein, the term "plant substance" includes any material derived from a plant, including but not limited to extracts, leaves, bark, fibers, stems, roots, seeds, flowers, fruits, pollen, skin, husks, etc. Alternatively, the material may include an active compound that is synthetically obtained and naturally present in a plant substance. The material may be in the form of a liquid, gas, solid, powder, dust, crushed particles, granules, pellets, fragments, chips, sheets, etc. Example plant substances are tobacco, eucalyptus, star anise, hemp, cocoa, cannabis, fennel, lemongrass, peppermint, spearmint, rooibos, chamomile, flax, ginger, ginkgo leaf, nettle, hibiscus, laurel, licorice, matcha, mate, orange peel, papaya, rose, sage, teas such as green tea or black tea, thyme, clove, cinnamon, coffee, aniseed (anis), basil, bay leaf, cardamom, coriander, cumin, nutmeg, oregano, paprika, rosemary, saffron, lavender, lemon peel, mint, vaccinium, nasturtium flower, vanilla, wintergreen, perilla, turmeric, curcuma, aconite, calamus, bergamot, orange flower, kinkan, kurofusa suguri, kanoko sou, pimento, mace, damiana, marjoram, olive, lemon balm, lemon basil, chive, carvi, vervain, tarragon, geranium, mulberry, burdock, theanine, theacrine, maca, ashwagandha, damiana, guarana, chlorophyll, baobab or any combination thereof.The mint may be selected from the following mint varieties: Hacker (Mentha Arventis), Moroccan Mint (Mentha c.v.), Egyptian Mint (Mentha niliaca), Peppermint (Mentha piperita), Odoratum Mint (Mentha piperita citrata c.v.), Candy Mint (Mentha piperita c.v), Curly Mint (Mentha spicata crispa), Kentucky Kernel Mint (Mentha cardifolia), Horsemint (Memtha longifolia), Pineapple Mint (Mentha suaveolens variegata), Pennyroyal Mint (Mentha pulegium), English Mint (Mentha spicata c.v.) and Apple Mint (Mentha suaveolens).

[0032] In some embodiments, the active agent comprises or is derived from one or more plant substances or their components, derivatives or extracts, and the plant substance is tobacco.

[0033] In some embodiments, the active agent comprises or is derived from one or more plant substances or their components, derivatives or extracts, and the plant substance is selected from eucalyptus, star anise, cocoa and hemp.

[0034] In some embodiments, the active agent comprises or is derived from one or more plant substances or their components, derivatives or extracts, and the plant substance is selected from rooibos and fennel.

[0035] In one embodiment, the one or more active agents are present in a combined amount of 6 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.01 - 6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.02 - 6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.05 - 6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.08 - 6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.01 - 5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.02 - 5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.05 - 5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.08 - 5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 4 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the one or more active agents are present in an amount of 0.01 to 4 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 4 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 4 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.08 to 4 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 3 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.01 to 3 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 3 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 3 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.08 to 3 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 2 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the one or more active agents are present in an amount of 0.01 to 2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.08 to 2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 1 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.01 to 1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.08 to 1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.1 to 1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the one or more active agents are present in a combined amount of 0.6 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.01 - 0.6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.02 - 0.6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.05 - 0.6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.08 - 0.6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.1 - 0.6 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.5 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.01 - 0.5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.02 - 0.5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in a combined amount of 0.05 - 0.5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the one or more active agents are present in an amount of 0.08 to 0.5 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.2 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.01 to 0.2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 0.2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 0.2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.08 to 0.2 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.1 wt% or less (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.01 to 0.1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.02 to 0.1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the one or more active agents are present in an amount of 0.05 to 0.1 wt% (such that nicotine is present in an amount) based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the one or more active agents are present in an amount combined (such that nicotine is present in an amount) of 0.08 to 0.1 wt% based on an aerosolizable formulation or an aerosolized formulation.

[0036] Acid As discussed above, the aerosolizable formulations and aerosolized formulations of the present invention may contain one or more additional components. These components may be selected according to the nature of the formulation. In one embodiment, the aerosolizable formulation and the aerosolized formulation further contain an acid.

[0037] In one embodiment, the acid is an organic acid. In one embodiment, the acid is a carboxylic acid. In one embodiment, the acid is an organic carboxylic acid.

[0038] In one embodiment, the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof. In one embodiment, the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, lactic acid, sorbic acid, and mixtures thereof. In one embodiment, the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, and mixtures thereof. In one embodiment, the acid is at least citric acid. In one embodiment, the acid consists of citric acid.

[0039] In one embodiment, the acid is selected from acids having a pka of 2 to 5. In one embodiment, the acid is a weak acid. In one embodiment, the acid is a weak organic acid.

[0040] In one embodiment, the acid has a water solubility of at least 5 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 10 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 20 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 50 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 100 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 2OO g / L at 20°C. In one embodiment, the acid has a water solubility of at least 300 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 400 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 500 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 600 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 700 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 800 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 900 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 1000 g / L at 20°C. In one embodiment, the acid has a water solubility of at least 1100 g / L at 20°C.

[0041] The molar ratio of the acid to the activator (such as nicotine) may be selected as desired. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 5:1 to 1:5. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 4:1 to 1:4. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 3:1 to 1:3. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 2:1 to 1:2. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 1.5:1 to 1:1.5. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 1.2:1 to 1:1.2. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 5:1 to 1:1. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 4:1 to 1:1. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 3:1 to 1:1. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 2:1 to 1:1. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 1.5:1 to 1:1. In one embodiment, the molar ratio of the acid to the activator (such as nicotine) is from 1.2:1 to 1:1.

[0042] In one embodiment, the total content of the acid present in the formulation is 5 molar equivalents or less based on the activator (such as nicotine). In one embodiment, the total content of the acid present in the formulation is 4 molar equivalents or less based on the activator (such as nicotine). In one embodiment, the total content of the acid present in the formulation is 3 molar equivalents or less based on the activator (such as nicotine). In one embodiment, the total content of the acid present in the formulation is 2 molar equivalents or less based on the activator (such as nicotine). In one embodiment, the total content of the acid present in the formulation is 1 molar equivalent or less based on the activator (such as nicotine).

[0043] In one embodiment, the total acid content present in the formulation is at least 0.01 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.05 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.1 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.2 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.3 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.4 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.5 molar equivalents based on the active agent (such as nicotine). In one embodiment, the total acid content present in the formulation is at least 0.7 molar equivalents based on the active agent (such as nicotine).

[0044] In one embodiment, the acid is present in an amount of 6 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 - 6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 - 6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 - 5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 - 5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 4 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 4 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 4 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 - 4 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 - 4 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 3 wt% or less based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the acid is present in an amount of 0.01 to 3 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 to 3 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 to 3 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 to 3 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 2 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 to 2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 to 2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 to 2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 to 2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 1 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 to 1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 to 1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 to 1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 to 1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.1 to 1 wt% based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the acid is present in an amount of 0.6 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 0.6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 0.6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 - 0.6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 - 0.6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.1 - 0.6 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.5 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 0.5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 0.5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 - 0.5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 - 0.5 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.2 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 - 0.2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 - 0.2 wt% based on the aerosolizable formulation or the aerosolized formulation.In one embodiment, the acid is present in an amount of 0.05 to 0.2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 to 0.2 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.1 wt% or less based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.01 to 0.1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.02 to 0.1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.05 to 0.1 wt% based on the aerosolizable formulation or the aerosolized formulation. In one embodiment, the acid is present in an amount of 0.08 to 0.1 wt% based on the aerosolizable formulation or the aerosolized formulation.

[0045] The amount of acid and the solubility of the acid may be selected such that a given amount of the acid dissolves in water. In one embodiment, at least 20% of the acid dissolves in water at 20°C. In one embodiment, at least 20% of the acid dissolves in water at 25°C. In one embodiment, at least 20% of the acid dissolves in water at 30°C. In one embodiment, at least 35% of the acid dissolves in water at 20°C. In one embodiment, at least 40% of the acid dissolves in water at 20°C. In one embodiment, at least 45% of the acid dissolves in water at 20°C. In one embodiment, at least 50% of the acid dissolves in water at 20°C. In one embodiment, at least 55% of the acid dissolves in water at 20°C.

[0046] As will be understood by those skilled in the art, nicotine may exist in a non-protonated form, a monoprotonated form, or a diprotonated form. The structures of each of these forms are shown below.

Chemical formula

[0047] As used herein, the term "protonated form" means both monoprotonated nicotine and diprotonated nicotine. As used herein, the term "amount of protonated form" means the combined amount of monoprotonated nicotine and diprotonated nicotine. Further, when referring to a fully protonated formulation, it will be understood that at any given time, there may be present a very small amount of unprotonated nicotine, e.g., less than 1% unprotonated nicotine.

[0048] The formulation may contain nicotine in protonated form. The formulation may contain nicotine in unprotonated form. In one embodiment, the formulation contains nicotine in unprotonated form and in monoprotonated form. In one embodiment, the formulation contains nicotine in unprotonated form and in diprotonated form. In one embodiment, the formulation contains nicotine in unprotonated form, in monoprotonated form, and in diprotonated form.

[0049] In one embodiment, at least 5 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 10 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 15 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 20 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 25 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 30 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 35 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 40 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 45 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 50 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 55 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 60 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 65 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 70 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 75 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 80 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 85 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 90 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 95 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 99 wt% of the nicotine present in the formulation is in the protonated form. In one embodiment, at least 99.9 wt% of the nicotine present in the formulation is in the protonated form.

[0050] In one aspect, 50 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 55 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 60 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 65 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 70 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 75 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 80 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 85 - 95 wt% of the nicotine present in the formulation is in the protonated form. In one aspect, 90 - 95 wt% of the nicotine present in the formulation is in the protonated form.

[0051] The relevant amounts of nicotine present in the formulation in the protonated form are specified herein. These amounts can be readily calculated by one skilled in the art. Nicotine (3-(1-methylpyrrolidin-2-yl)pyridine) is a dibasic base with a pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring. Nicotine can exist in pH-dependent protonated (mono- and di-) forms and non-protonated (free base) forms with different bioavailabilities.

Chemical formula

[0052] The distribution of protonated and non-protonated nicotine will change with various pH increases.

Chemical formula

[0053] The proportion of non-protonated nicotine becomes dominant at high pH levels, while a decrease in pH will result in an increase in the proportion of protonated nicotine (mono- or di- depending on pH). If the relative proportion of protonated nicotine in the sample and the total amount of nicotine are known, the absolute amount of protonated nicotine can be calculated.

[0054] The relative proportion of protonated nicotine in the formulation can be calculated by using the Henderson-Hasselbalch equation that expresses pH as a derivation of the acid dissociation constant formula, and the Henderson-Hasselbalch equation is widely used in chemical and biological systems. Consider the following equilibrium:

Chemical formula

[0055] The Henderson-Hasselbalch equation for this equilibrium is:

Mathematical formula

[0056] In the formula, [B] is the amount of non-protonated nicotine (i.e., free base), [BH+] is the amount of protonated nicotine (i.e., conjugate acid), and pKa is the reference pKa value of the pyrrolidine ring nitrogen of nicotine (pKa = 8.02). The relative proportion of protonated nicotine can be derived from the alpha value of non-protonated nicotine calculated from the Henderson-Hasselbalch equation as follows:

Mathematical formula

[0057] The determination of the pKa value of the nicotine formulation was carried out using the basic method described in "Spectroscopic investigations into the acid-base properties of nicotine at different temperatures", Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, Anal. Methods, 2013, 5, 81-88.

[0058] Complex One or more cyclodextrins may or may not be present in any suitable amount in the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 12 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 10 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 9 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 8 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 7 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 6 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 5 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 4 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 3 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 2 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 1 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.5 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.1 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.01 wt.% or less based on the aerosolizable formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.001 wt.% or less based on the aerosolizable formulation.

[0059] One or more cyclodextrins may or may not be present in any suitable amount in the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 12 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 10 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 9 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 8 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 7 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 6 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 5 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 4 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 3 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 2 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 1 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.5 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.1 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.01 wt.% or less based on the aerosolized formulation. In one embodiment, one or more cyclodextrins are present in a total amount of 0.001 wt.% or less based on the aerosolized formulation.

[0060] One or more cyclodextrins may be selected from the group consisting of unsubstituted cyclodextrins, substituted cyclodextrins, and mixtures thereof. In one embodiment, at least one cyclodextrin is an unsubstituted cyclodextrin. In one embodiment, one or more cyclodextrins are selected from the group consisting of unsubstituted cyclodextrins. In one embodiment, at least one cyclodextrin is a substituted cyclodextrin. In one embodiment, one or more cyclodextrins are selected from the group consisting of substituted cyclodextrins.

[0061] In one embodiment, one or more cyclodextrins are selected from the group consisting of unsubstituted (α)-cyclodextrin, substituted (α)-cyclodextrin, unsubstituted (β)-cyclodextrin, substituted (β)-cyclodextrin, unsubstituted (γ)-cyclodextrin, substituted (γ)-cyclodextrin, and mixtures thereof. In one embodiment, one or more cyclodextrins are selected from the group consisting of unsubstituted (β)-cyclodextrin, substituted (β)-cyclodextrin, and mixtures thereof.

[0062] In one embodiment, one or more cyclodextrins are selected from the group consisting of unsubstituted (α)-cyclodextrin, unsubstituted (β)-cyclodextrin, unsubstituted (γ)-cyclodextrin, and mixtures thereof. In one embodiment, one or more cyclodextrins are selected from unsubstituted (β)-cyclodextrin.

[0063] In one embodiment, one or more cyclodextrins are selected from the group consisting of substituted (α)-cyclodextrin, substituted (β)-cyclodextrin, substituted (γ)-cyclodextrin, and mixtures thereof. In one embodiment, one or more cyclodextrins are selected from substituted (β)-cyclodextrin. Chemical substitutions at the 2-, 3-, and 6-hydroxyl sites, particularly substitution at the 2-position, are contemplated.

[0064] In one embodiment, the one or more cyclodextrins are selected from the group consisting of 2-hydroxypropyl-α-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 2-hydroxypropyl-γ-cyclodextrin, and mixtures thereof. In one embodiment, the one or more cyclodextrins are at least 2-hydroxypropyl-α-cyclodextrin. In one embodiment, the one or more cyclodextrins are at least 2-hydroxypropyl-β-cyclodextrin. In one embodiment, the one or more cyclodextrins are at least 2-hydroxypropyl-γ-cyclodextrin.

[0065] 2-Hydroxypropyl derivatives of cyclodextrins, such as 2-hydroxypropyl-β-cyclodextrin, have increased water solubility when compared to the parent cyclodextrin, such as β-cyclodextrin.

[0066] In one embodiment, when the aerosolizable formulation contains one or more cyclodextrins, the aerosolizable formulation does not contain a fragrance that can be encapsulated by the one or more cyclodextrins.

[0067] Method As discussed herein, in one embodiment, a method for generating an aerosol, (i) water in an amount of at least 50 wt.% based on the aerosolized formulation, and (ii) at least one fragrance is provided, which comprises aerosolizing an aerosolizable formulation comprising the same to produce an aerosol comprising at least one fragrance in an amount of at least 70 wt.% of the fragrance present in the aerosolizable formulation.

[0068] In this method, the aerosol may be generated by a method carried out at a temperature below 60°C. In the method, the aerosol may be generated by a method carried out at a temperature below 50°C. In the method, the aerosol may be generated by a method carried out at a temperature below 40°C. In the method, the aerosol may be generated by a method carried out at a temperature below 30°C. In the method, the aerosol may be generated by a method carried out at a temperature below 25°C. In the method, the aerosol may be generated by a method without heating.

[0069] In the method, the aerosol may be generated by applying ultrasonic energy to an aerosolizable formulation.

[0070] In one embodiment, the aerosol of the aerosolized formulation has a D50 of 2 - 6 μm. References herein to particle size distribution, D50, D10 or D90 refer to values measured in accordance with the British and European Pharmacopoeia, 2.9.31 Particle Size Analysis By Laser Light Diffraction (BRITISH PHARMACOPOEIA COMMISSION. (2014), British Pharmacopoeia. London, England: Stationery Office and COUNCIL OF EUROPE. (2013). European Pharmacopoeia. Strasbourg, France: Council of Europe). The terms D50, Dv50 and Dx50 are interchangeable. The terms D10, Dv10 and Dx10 are interchangeable. The terms D90, Dv90 and Dx90 are interchangeable.

[0071] In one aspect, the aerosol has a D50 of 2.5 to 6 μm. In one aspect, the aerosol has a D50 of 3 to 6 μm. In one aspect, the aerosol has a D50 of 3.5 to 6 μm. In one aspect, the aerosol has a D50 of 4 to 6 μm. In one aspect, the aerosol has a D50 of 4.5 to 6 μm. In one aspect, the aerosol has a D50 of 5 to 6 μm. In one aspect, the aerosol has a D50 of 2.5 to 5.5 μm. In one aspect, the aerosol has a D50 of 3 to 5.5 μm. In one aspect, the aerosol has a D50 of 3.5 to 5.5 μm. In one aspect, the aerosol has a D50 of 4 to 5.5 μm. In one aspect, the aerosol has a D50 of 4.5 to 5.5 μm. In one aspect, the aerosol has a D50 of 5 to 5.5 μm.

[0072] In one aspect, the aerosol has a D10 of at least 0.5 μm. In one aspect, the aerosol has a D10 of at least 1 μm. In one aspect, the aerosol has a D10 of at least 2 μm.

[0073] In one aspect, the aerosol has a D90 of 15 μm or less. In one aspect, the aerosol has a D90 of 12 μm or less. In one aspect, the aerosol has a D90 of 10 μm or less.

[0074] In one aspect, D50 is measured after excluding particles having a particle size of less than 1 μm. In one aspect, D10 is measured after excluding particles having a particle size of less than 1 μm. In one aspect, D90 is measured after excluding particles having a particle size of less than 1 μm.

[0075] The complex may be contained or delivered by any means. In one aspect, the present invention provides a contained aerosolizable formulation comprising (a) one or more containers and (b) an aerosolizable formulation as defined herein. The container may be any suitable container, for example, to enable storage or delivery of the formulation. In one aspect, the container is configured to engage with an electronic aerosol supply system. The container may be configured to be in fluid communication with the electronic aerosol supply system such that the formulation can be delivered to the electronic aerosol supply system. As described above, the present disclosure relates to a container that can be used in an electronic aerosol supply system such as an e-cigarette. Throughout the following description, the term "e-cigarette" is used, but this term can be used interchangeably with an electronic aerosol supply system.

[0076] As discussed herein, the containers of the present invention are typically provided for the delivery of an aerosolizable formulation to or within an e-cigarette. The aerosolizable formulation may be retained within the e-cigarette or may be sold as a separate container for subsequent use with or within the e-cigarette. As will be understood by those skilled in the art, an e-cigarette typically includes a reservoir for the aerosolizable formulation, an aerosolization device such as a wicking material, and a removable cartridge known as a unit that typically includes a heating element for vaporizing the aerosolizable formulation. In some e-cigarettes, the cartridge is part of an integrated device and is not removable. In one aspect, the container is the cartridge or part of the cartridge. In one aspect, the container is not the cartridge or part of the cartridge, but is a container such as a tank, and the container can be used to deliver a nicotine formulation to or within an e-cigarette.

[0077] In one aspect, the container is part of an e-cigarette. Thus, in a further aspect, the present invention provides an electronic aerosol supply system comprising an aerosolizable formulation as defined herein, an aerosolization device for aerosolizing the formulation for inhalation by a user of the electronic aerosol supply system, and a power source comprising a battery or battery for powering the aerosolization device.

[0078] In addition to the aerosolizable formulations of the present invention and systems such as containers and electronic aerosol supply systems for containing them, the present invention provides methods for improving the sensory properties of aerosolized nicotine. In a further aspect, the present invention provides methods for improving the storage stability of aerosolized nicotine formulations.

[0079] Reference to improving the sensory properties of the vaporized nicotine solution may include improving the smoothness of the vaporized nicotine solution as perceived by the user.

[0080] The methods of the present invention may include additional steps either before, after, or in between one or more of the recited steps.

[0081] Reference is now made to the following accompanying drawings, which illustrate the invention by way of example and in which: BRIEF DESCRIPTION OF THE DRAWINGS

[0082]

Figure 1

[0083] Reference is now made to the following non-limiting examples, which illustrate the invention.

[0084] Example 1 A series of tests were conducted using a formulation containing 90.0% (w / w) water, 9.0% 2-hydroxypropyl-β-cyclodextrin, 0.9% l-menthol, and 0.1% nicotine.

[0085] In this embodiment, the measurement of menthol and nicotine is performed by a suitable detection mechanism such as gas chromatography and flame ionization detection (CG-FID).

[0086] Upon aerosolization, the complex formation mechanism between l-menthol and 2-hydroxypropyl-β-cyclodextrin becomes dynamic due to the transfer of kinetic energy from the device to the formulation. Thus, if the aerosol transit time is long enough, menthol can return as a guest molecule into the host 2-hydroxypropyl-β-cyclodextrin.

[0087] The experiment was designed to collect the condensed formulation on a surface colder than the surroundings to achieve equivalent measurements of menthol and nicotine after aerosolization. Since energy transfer is expected to release l-menthol from the host 2-hydroxypropyl-β-cyclodextrin, any differences between before and after aerosolization may be due to the release of l-menthol as a vapor due to the hydrophobic behavior of l-menthol. It should be noted that the behavior of nicotine is excluded in this example since nicotine is expected to dissolve in water and be trapped within the water droplets of the particulate phase.

[0088] In practice, since the complex formation mechanism is dynamic, the inventors expect negligible differences between the formulations before and after aerosolization. This is the effect observed using GC-FID as the measurement system. A tolerance of ±10% is suitable in this case.

[0089] Example 2 A series of formulations prepared by the inventors according to the described method and tested by an analytical laboratory with respect to flavor compounds.

[0090] Water 83.1% (w / w), 2-hydroxypropyl-β-cyclodextrin 15.0% (w / w), l-menthol 0.9% (w / w) and nicotine 1% (w / w); and Water 98.8% (w / w), vanillin 0.6% (w / w) and nicotine 0.6% (w / w) The device was filled with the formulations containing

[0091] In both examples, a commercially available nebulizer was used to aerosolize the formulations, and the generated aerosol was collected on a 44 mm Cambridge filter pad (CFP), and subsequently collected with two impingers connected in series containing isopropyl alcohol and an internal standard for quantification. This was done so that both the gas phase and the droplet phase were captured for analysis. Aerosol generation and sample analysis of both formulations were performed in triplicate. Analytical tests were performed using gas chromatography (Agilent 7890A gas chromatograph or equivalent) coupled with a mass spectrometer (Markes Bench time-of-flight or equivalent). For each repetition, 20 puffs were collected using a single-port smoking machine such as Borgwaldt LX or equivalent. The weight of the CFP was recorded before and after aerosol collection. Subsequently, the CFP was extracted using the combined solution from both impingers and analyzed for the target compounds. Before analysis, a five-point calibration curve was created using high-purity standards for quantification purposes. The formulations were analyzed before aerosolization to show the amount of flavoring before and after the process.

[0092] Liquid analysis of the formulation containing l-menthol showed l-menthol 0.8% (w / w) (8 mg / g) and nicotine 1.0% (w / w) (10 mg / g). Aerosol analysis of the same formulation showed l-menthol 0.7 - 0.8% (w / w) (7 - 8 mg / g) and nicotine 1 - 1.1% (w / w) (10 - 11 mg / g).

[0093] Liquid analysis of the formulation containing vanillin showed 0.5% (w / w) (5 mg / g) of vanillin and 0.6% (w / w) (6 mg / g) of nicotine. Aerosol analysis of the same formulation showed 0.5 - 0.6% (w / w) (5 - 6 mg / g) of vanillin and 0.6% (w / w) (6 mg / g) of nicotine.

[0094] These results showed 100% recovery of flavor and nicotine and no degradation of the active ingredients during the aerosolization process.

[0095] Without departing from the scope and spirit of the present invention, various modifications and variations of the present invention will become apparent to those skilled in the art. While the present invention has been described in connection with specific preferred embodiments, it is to be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the chemical or related arts are intended to be within the scope of the following claims.

Claims

1. An aerosolized formulation comprising: (i) water in an amount of 50 to 99 wt.% based on the aerosolized formulation; (ii) at least one fragrance selected from the group consisting of vanillin, l-menthol, and mixtures thereof; (iii) an acid; and (iv) nicotine wherein the at least one fragrance is included in an amount of at least 70 wt.% of the at least one fragrance present in the aerosolizable formulation that produces the aerosolized formulation, and the molar ratio of acid to nicotine is from 5:1 to 1:

1. An aerosolized formulation.

2. The aerosolized formulation according to claim 1, wherein water is present in an amount of 75 to 99 wt.% based on the aerosolized formulation.

3. The aerosolized formulation according to claim 1 or 2, wherein water is present in an amount of 90 to 99 wt.% based on the aerosolized formulation.

4. The aerosolized formulation according to claim 1, wherein the at least one fragrance is l-menthol.

5. The aerosolized formulation according to any one of claims 1 to 4, wherein the at least one fragrance is present in a total amount of 0.01 to 2 wt.% based on the aerosolized formulation.

6. The aerosolized formulation according to any one of claims 1 to 5, wherein the at least one fragrance is present in a total amount of 0.01 to 1 wt.% based on the aerosolized formulation.

7. The aerosolized formulation according to any one of claims 1 to 6, wherein the at least one fragrance is included in an amount of at least 80 wt.% of the at least one fragrance present in the aerosolizable formulation that produces the aerosolized formulation.

8. The aerosolized formulation according to any one of claims 1 to 7, wherein the at least one fragrance is included in an amount of at least 90 wt.% of the at least one fragrance present in the aerosolizable formulation that produces the aerosolized formulation.

9. The aerosolized formulation according to any one of claims 1 to 8, comprising a mixture of vanillin and l-menthol.

10. The aerosolized formulation according to claim 9, wherein each of the vanillin and l-menthol is included in an amount of at least 70 wt% of each of the vanillin and l-menthol present in the aerosolizable formulation that generates the aerosolized formulation.

11. The aerosolized formulation according to any one of claims 1 to 10, further comprising one or more cyclodextrins.

12. The aerosolized formulation according to claim 1, wherein the nicotine is present in an amount of 0.01 to 1 wt.% based on the aerosolized formulation.

13. The aerosolized formulation according to claim 12, wherein the nicotine is present in an amount of 0.01 to 0.6 wt.% based on the aerosolized formulation.

14. The aerosolized formulation according to claim 1, wherein the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.

15. The aerosolized formulation according to claim 14, wherein the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, lactic acid, sorbic acid, and mixtures thereof.

16. The aerosolized formulation according to claim 14 or 15, wherein the acid is at least citric acid.

17. A method for producing the aerosolized formulation according to any one of claims 1 to 16, comprising: (i) water in an amount of 50 to 99 wt.% based on the aerosolized formulation; (ii) at least one fragrance selected from the group consisting of vanillin, l-menthol, and mixtures thereof; (iii) an acid; and (iv) nicotine comprising aerosolizing an aerosolizable formulation to produce an aerosolized formulation comprising the at least one fragrance in an amount of at least 70 wt% of the at least one fragrance present in the aerosolizable formulation, and wherein the molar ratio of acid to nicotine is from 5:1 to 1:

1.

18. The method according to claim 17, wherein the aerosolized formulation is produced by a method carried out at a temperature below 50°C.

19. The method according to claim 17 or 18, wherein the aerosolized formulation is produced by applying ultrasonic energy to the aerosolizable formulation.

20. An electronic aerosol supply system, comprising: (a) an aerosolization device for aerosolizing a formulation for inhalation by a user of the electronic aerosol supply system; (b) a power source including a battery or batteries for supplying power to the aerosolization device; (c) (i) water in an amount of 50 to 99 wt.% based on the aerosolized formulation; (ii) at least one fragrance selected from the group consisting of vanillin, l-menthol, and mixtures thereof; (iii) an acid; and (iv) nicotine and an aerosolizable formulation containing the same, wherein the aerosolization device contains the at least one fragrance in an amount of at least 70 wt.% of the at least one fragrance present in the aerosolizable formulation, and the molar ratio of acid to nicotine is from 5:1 to 1:1, for producing an aerosolized formulation according to any one of claims 1 to 16. An electronic aerosol supply system.

21. A method for improving the delivery of a fragrance to an aerosolized formulation, comprising: (a) (i) preparing an aerosolizable material containing water in an amount of 50 to 99 wt.% based on the aerosolizable material, (ii) at least one fragrance selected from the group consisting of vanillin, l-menthol, and mixtures thereof, (iii) an acid, and (iv) nicotine; (b) aerosolizing the aerosolizable material to produce an aerosol containing the at least one fragrance in an amount of at least 70 wt.% of the at least one fragrance present in the aerosolizable formulation, and the molar ratio of acid to nicotine is from 5:1 to 1:

1. A method. ​

Images